[1]
“Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model”, FE, vol. 14, no. 2, pp. 51–74, Apr. 2013, doi: 10.7175/fe.v14i2.651.